Vaxcyte Stock Alpha and Beta Analysis
| PCVX Stock | USD 46.59 1.45 3.02% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Vaxcyte. It also helps investors analyze the systematic and unsystematic risks associated with investing in Vaxcyte over a specified time horizon. Remember, high Vaxcyte's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Vaxcyte's market risk premium analysis include:
Beta 0.91 | Alpha 0.0752 | Risk 2.91 | Sharpe Ratio 0.0593 | Expected Return 0.17 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Vaxcyte Backtesting, Vaxcyte Valuation, Vaxcyte Correlation, Vaxcyte Hype Analysis, Vaxcyte Volatility, Vaxcyte History and analyze Vaxcyte Performance. Vaxcyte Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Vaxcyte market risk premium is the additional return an investor will receive from holding Vaxcyte long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vaxcyte. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Vaxcyte's performance over market.| α | 0.08 | β | 0.91 |
Vaxcyte expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Vaxcyte's Buy-and-hold return. Our buy-and-hold chart shows how Vaxcyte performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Vaxcyte Market Price Analysis
Market price analysis indicators help investors to evaluate how Vaxcyte stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vaxcyte shares will generate the highest return on investment. By understating and applying Vaxcyte stock market price indicators, traders can identify Vaxcyte position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Price Ceiling Movement | ||
| Tangent Of Price Series | ||
| Aroon Oscillator | ||
| Aroon Oscillator | ||
| Kaufman Adaptive Moving Average | ||
| Bollinger Bands | ||
| Rickshaw Man | ||
| Harami Cross Pattern |
Vaxcyte Return and Market Media
The median price of Vaxcyte for the period between Mon, Oct 20, 2025 and Sun, Jan 18, 2026 is 45.55 with a coefficient of variation of 5.18. The daily time series for the period is distributed with a sample standard deviation of 2.35, arithmetic mean of 45.43, and mean deviation of 1.92. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Will Vaxcyte Inc. stock continue upward momentum - GDP Growth Community Verified Trade Signals - newser.com | 11/03/2025 |
2 | Disposition of 74000 shares by Wassil Jim of Vaxcyte subject to Rule 16b-3 | 12/03/2025 |
3 | Vaxcyte, Inc. Makes Strides on Pneumonia Treatment, Plots Coverage Extension | 12/11/2025 |
4 | Pivotal OPUS Phase 3 VAX-31 Head-to-Head Trial Could Be A Game Changer For Vaxcyte | 12/15/2025 |
5 | Disposition of 1000 shares by Elvia Cowan of Vaxcyte subject to Rule 16b-3 | 12/23/2025 |
6 | Insider Selling Vaxcyte SVP Sells 11,623 Shares of Stock - MarketBeat | 12/29/2025 |
7 | Disposition of 9743 shares by Dhaliwal Harpreet S. of Vaxcyte at 46.689 subject to Rule 16b-3 | 12/31/2025 |
8 | Vaxcyte Gains Positive Outlook with Price Target Boost - GuruFocus | 01/07/2026 |
9 | Vaxcyte, Inc. Stock Analysis A Look At Its 121.74 percent Potential Upside - DirectorsTalk Interviews | 01/12/2026 |
10 | Acquisition by Brandicourt Olivier of 1357 shares of Vaxcyte subject to Rule 16b-3 | 01/15/2026 |
About Vaxcyte Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Vaxcyte or other stocks. Alpha measures the amount that position in Vaxcyte has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 7.54 | 12.75 | 11.48 | 8.48 | Net Debt To EBITDA | 0.94 | 0.71 | 0.81 | 0.77 |
Vaxcyte Upcoming Company Events
As portrayed in its financial statements, the presentation of Vaxcyte's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vaxcyte's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Vaxcyte's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Vaxcyte. Please utilize our Beneish M Score to check the likelihood of Vaxcyte's management manipulating its earnings.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Vaxcyte
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.